326 related articles for article (PubMed ID: 25620094)
1. Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments.
Ji YT; Liu YN; Liu ZP
Curr Med Chem; 2015; 22(11):1348-60. PubMed ID: 25620094
[TBL] [Abstract][Full Text] [Related]
2. Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
Cai SX
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):79-101. PubMed ID: 18221055
[TBL] [Abstract][Full Text] [Related]
3. Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents.
Duan Y; Liu W; Tian L; Mao Y; Song C
Curr Top Med Chem; 2019; 19(15):1289-1304. PubMed ID: 31210108
[TBL] [Abstract][Full Text] [Related]
4. Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth.
Pérez-Pérez MJ; Priego EM; Bueno O; Martins MS; Canela MD; Liekens S
J Med Chem; 2016 Oct; 59(19):8685-8711. PubMed ID: 27348355
[TBL] [Abstract][Full Text] [Related]
5. Antivascular and antitumor properties of the tubulin-binding chalcone TUB091.
Canela MD; Noppen S; Bueno O; Prota AE; Bargsten K; Sáez-Calvo G; Jimeno ML; Benkheil M; Ribatti D; Velázquez S; Camarasa MJ; Díaz JF; Steinmetz MO; Priego EM; Pérez-Pérez MJ; Liekens S
Oncotarget; 2017 Feb; 8(9):14325-14342. PubMed ID: 27224920
[TBL] [Abstract][Full Text] [Related]
6. Vascular disrupting agents: a new class of drug in cancer therapy.
Gaya AM; Rustin GJ
Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):277-90. PubMed ID: 15997924
[TBL] [Abstract][Full Text] [Related]
7. Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI.
Kim KW; Lee JM; Jeon YS; Lee IJ; Choi Y; Park J; Kiefer B; Kim C; Han JK; Choi BI
Invest New Drugs; 2013 Oct; 31(5):1097-106. PubMed ID: 23299389
[TBL] [Abstract][Full Text] [Related]
8. Medicinal chemistry and chemical biology of diketopiperazine-type antimicrotubule and vascular-disrupting agents.
Hayashi Y; Yamazaki-Nakamura Y; Yakushiji F
Chem Pharm Bull (Tokyo); 2013; 61(9):889-901. PubMed ID: 23995353
[TBL] [Abstract][Full Text] [Related]
9. [Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents].
Cai YC; Zou Y; Xian LJ
Yao Xue Xue Bao; 2010 Mar; 45(3):283-8. PubMed ID: 21351502
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in research of colchicine binding site inhibitors and their interaction modes with tubulin.
Sun K; Sun Z; Zhao F; Shan G; Meng Q
Future Med Chem; 2021 May; 13(9):839-858. PubMed ID: 33821673
[TBL] [Abstract][Full Text] [Related]
11. Current development status of small-molecule vascular disrupting agents.
Chaplin DJ; Horsman MR; Siemann DW
Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
[TBL] [Abstract][Full Text] [Related]
12. A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.
Mason RP; Zhao D; Liu L; Trawick ML; Pinney KG
Integr Biol (Camb); 2011 Apr; 3(4):375-87. PubMed ID: 21321746
[TBL] [Abstract][Full Text] [Related]
13. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
[TBL] [Abstract][Full Text] [Related]
14. Vascular disrupting agents.
Lippert JW
Bioorg Med Chem; 2007 Jan; 15(2):605-15. PubMed ID: 17070061
[TBL] [Abstract][Full Text] [Related]
15. Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis.
Banerjee S; Hwang DJ; Li W; Miller DD
Molecules; 2016 Nov; 21(11):. PubMed ID: 27827858
[TBL] [Abstract][Full Text] [Related]
16. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
Wang Y; Zhang H; Gigant B; Yu Y; Wu Y; Chen X; Lai Q; Yang Z; Chen Q; Yang J
FEBS J; 2016 Jan; 283(1):102-11. PubMed ID: 26462166
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site.
Wu X; Wang Q; Li W
Anticancer Agents Med Chem; 2016; 16(10):1325-38. PubMed ID: 26899186
[TBL] [Abstract][Full Text] [Related]
18. AVE8062: a new combretastatin derivative vascular disrupting agent.
Delmonte A; Sessa C
Expert Opin Investig Drugs; 2009 Oct; 18(10):1541-8. PubMed ID: 19758109
[TBL] [Abstract][Full Text] [Related]
19. Molecular modelling studies on Arylthioindoles as potent inhibitors of tubulin polymerization.
Coluccia A; Sabbadin D; Brancale A
Eur J Med Chem; 2011 Aug; 46(8):3519-25. PubMed ID: 21621885
[TBL] [Abstract][Full Text] [Related]
20. New indole-based chalconoids as tubulin-targeting antiproliferative agents.
Mirzaei H; Shokrzadeh M; Modanloo M; Ziar A; Riazi GH; Emami S
Bioorg Chem; 2017 Dec; 75():86-98. PubMed ID: 28922629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]